Search
Deferoxamine
go.drugbank.com/drugs/DB00746ApprovedInvestigationalIt forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Deferrioxamine BBusulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalAccording to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. … Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 1, 4-Bis[methanesulfonoxy]butaneEstradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnEstradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. … As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located
Categories: Cytochrome P-450 CYP1A1 Substrates, P-glycoprotein substratesAripiprazole
go.drugbank.com/drugs/DB01238ApprovedInvestigationalAripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. … [L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein inhibitorsProducts: MENXELTI ® 5 MG, ABILIFY 1 MG/ML LSG Z EINNGliquidone
go.drugbank.com/drugs/DB01251ApprovedGliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. … This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesUrokinase
go.drugbank.com/drugs/DB00013ApprovedInvestigationalWithdrawnUrokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. … [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]
Products: Kinlytic Open-cath, UROKINASE KGCC INJ. 250000 IU FLAKON, 1 ADETPatiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalEach gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. … Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015.
Categories: Compounds used in a research, industrial, or household settingDaraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Neurokinin 1 AntagonistsTeriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalIt is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. … Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersSynonyms: (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidide